Aspen Pharmacare, a leading global pharmaceutical company headquartered in South Africa (ZA), has established itself as a key player in the healthcare industry since its founding in 1850. With a strong presence in over 50 countries, Aspen operates primarily in the areas of generic and branded pharmaceuticals, as well as consumer healthcare products.
The company is renowned for its diverse portfolio, which includes anaesthetics, thrombosis, and oncology medications, setting it apart through a commitment to quality and innovation. Aspen's strategic acquisitions and partnerships have bolstered its market position, making it one of the largest pharmaceutical manufacturers in Africa. Notable achievements include its rapid expansion into international markets and a focus on sustainable healthcare solutions, reinforcing its reputation as a trusted provider in the global pharmaceutical landscape.
+11 vs industry average
Aspen Pharmacare’s score of 40 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Aspen Pharmacare?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Research Services has typical carbon intensity
Industry performance
The Research Services industry has increased its overall emissions by 17% since 2019
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Aspen Pharmacare's reported carbon emissions
In 2025, Aspen Pharmacare reported total carbon emissions of approximately 148,281,000 kg CO2e, comprising 32,776,000 kg CO2e from Scope 1 and 115,505,000 kg CO2e from Scope 2 emissions. The company has set ambitious climate commitments, aiming to reduce global carbon dioxide emissions by 45% by 2030 relative to 2010 levels, with a long-term goal of achieving net zero emissions around mid-century. This commitment encompasses all scopes of emissions. Aspen has made significant strides in reducing its carbon footprint, with a target to cut absolute combined Scope 1 and Scope 2 emissions by 50% by 2030, based on a 2020 baseline. The company has also previously achieved a 64% reduction in Scope 1 emissions from 2012 to 2013 and a 44% reduction in Scope 2 emissions during the same period. Despite these efforts, Aspen has not disclosed Scope 3 emissions data, which includes emissions from purchased goods and services, business travel, and employee commuting. The company continues to focus on enhancing its sustainability practices and reducing its overall environmental impact.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Aspen Pharmacare’s Climate Goals (2030 & 2050)
6 goals2030
30% reduction in Scope 1
We are committed to reducing our Scope 1 emissions by 30% from a 2020 baseline by 2030.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 6 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
4 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Aspen Pharmacare
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project